Non-steroidal anti-inflammatory drugs attenuate the vascular responses in aging metabolic syndrome rats

Acta Pharmacologica Sinica

Volumn 35, Issue 11, 2014, Pages 1364-1374

  Rubio Ruiz, María Esther ^a   Pérez Torres, Israel ^a   Diaz Diaz, Eulises ^b   Pavón, Natalia ^c   Guarner Lans, Verónica ^a  

^a Department of Physiology ^*  (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

acetylcholine; aging; aortic ring; cyclooxygenase; cytokine; metabolic syndrome; norepinephrine; NSAID; vascular reactivity

Indexed keywords

ACETYLSALICYLIC ACID; DRINKING WATER; INDOMETACIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; ISOENZYME; MELOXICAM; NORADRENALIN; SUCROSE; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IL1B PROTEIN, RAT; MEMBRANE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PTGS1 PROTEIN, RAT; PTGS2 PROTEIN, RAT; TUMOR NECROSIS FACTOR; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA DISSECTION; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; MALE; METABOLIC SYNDROME X; NONHUMAN; PROTEIN EXPRESSION; RAT; VASCULAR RING; VASODILATATION; WESTERN BLOTTING; AGE; ANIMAL; AORTA; BLOOD; CHEMICALLY INDUCED; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; TIME FACTOR; VASOCONSTRICTION; WISTAR RAT;

AGE FACTORS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AORTA; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MEMBRANE PROTEINS; METABOLIC SYNDROME X; PHOSPHOLIPASES A2; RATS, WISTAR; SUCROSE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 84908465473     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2014.67     Document Type: Article

References (64)

1. Rubio-Ruiz ME, Guarner-Lans V. Inflammation and the use of antiinflammatory agents in signs and cardiovascular consequences of metabolic syndrome. In: Lopez-Garcia CM, Perez-Gonzalez PA, editors. Handbook on Metabolic syndrome. Classification, risk factors and health impact. New York: Nova Biomedical; 2012. p 169-88.
2. Shi Y, Man RY, Vanhoutte PM. Two isoforms of cyclooxygenase contribute to augmented endothelium-dependent contractions in femoral arteries of 1-year-old rats. Acta Pharmacol Sin 2008; 29: 185-92.
3. Goodwill AG, James ME, Frisbee JC. Increased vascular thromboxane generation impairs dilation of skeletal muscle arterioles of obese Zucker rats with reduced oxygen tension. Am J Physiol Heart Circ Physiol 2008; 295: H1522-8.
4. Xiang L, Naik JS, Hester RL. Functional vasodilation in the rat spinotrapezius muscle: role of nitric oxide, prostanoids and epoxyeicosatrienoic acids. Clin Exp Pharmacol Physiol 2008; 35: 617-24.
5. Guarner-Lans V, Rubio-Ruiz ME. Aging, metabolic syndrome and the heart. Aging Dis 2012; 3: 269-79.
6. Guarner-Lans V, Rubio-Ruiz ME, Pérez-Torres I, Baños de MacCarthy G. Relation of aging and sex hormones to metabolic syndrome and cardiovascular disease. Exp Gerontol 2011; 46: 517-23.
7. Chadha PS, Liu L, Rikard-Bell M, Senadheera S, Howitt L, Bertrand RL, et al. Endothelium-dependent vasodilation in human mesenteric artery is primarily mediated by myoendothelial gap junctions intermediate conductance calcium-activated K-channel and nitric oxide. J Pharmacol Exp Ther 2011; 336: 701-8.
8. Chennupati R, Lamers WH, Koehler SE, De Mey JG. Endotheliumdependent hyperpolarization-related relaxations diminish with age in murine saphenous arteries of both sexes. Br J Pharmacol 2013; 169: 1486-99.
9. Magen E, Viskoper JR, Mishal J, Priluk R, London D, Yodefy C. Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects. J Hum Hypertens 2005; 19: 667-73.
10. Deng S, Deng PY, Jiang JL, Ye F, Yu J, Yang TL, et al. Aspirin protected against enndothelial damage induced by LDL: role of endogenous NO synthase inhibitors in rats. Acta Pharmacol Sin 2004; 25: 1633-9.
11. Heymes C, Habid A, Yand D, Matthieu E, Marotte F, Samuel JL, et al. Cyclo-oxygenase-1 and -2 contribution to endothelial dysfunction in ageing. Br J Pharmacol 2000; 131: 804-10.
12. Cannon CP, Cannon PJ. COX-2 Inhibitors and cardiovascular risk. Science 2012; 336: 1386.
13. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-5.
14. McLean A, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2006; 56: 163-84.
15. Sumapa C, Allison JJ, Curtis JR. Risks versus benefits of cyclooxygenase- 2-selective nonsteroidal antiinflammatory drugs. Am J Health-Syst Pharm 2006; 63: 1837-51.
16. Wu R, Laplante MA, de Champlain J. Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats. Hypertension 2005; 45: 1139-44.
17. Bulckaen H, Prévost G, Boulanger E, Robitaille G, Roquet V, Gaxatte C, et al. Low-dose aspirin prevents age-related endothelial dysfunction in a mause model of physiological aging. Am J Physiol Heart Circ Physiol 2008; 294: H1562-70.
18. Raghavan RP, Laight DW, Shaw KM, Cummings MH. Aspirin and diabetes. Br J Diabetes Vasc Dis 2006; 6: 74-82.
19. Von der Weid P, Hollenberg MD, Fiorucci S, Wallace JL. Aspirin-Triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone. Circulation 2004; 110: 1320-5.
20. Wilson SL, Poulter NR. The effect of non-steroideal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J Hypertens 2006; 24: 1457-69.
21. Antman EM, De Mets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005; 112: 759-70.
22. Félétou M, Huang Y, Vanhoutte PM. Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol 2011; 164: 894-912.
23. White WB. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension 2007; 49: 408-18.
24. Geesaman BJ. Genetics of aging: implications for drug discovery and development. Am J Clin Nutr 2006; 83: 466S-469S.
25. Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM, et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 2001; 104: 820-5.
26. Jung SB, Kim CS, Naqvi A, Yamamori T, Mattagajasingh I, Hoffman TA, et al. Histone deacetylase 3 antagonizes aspirin-stimulated endothelial nitric oxide production by reversing aspirin-induced lysine acetylation of endothelial nitric oxide synthase. Circ Res 2010; 107: 877-87.
27. Baber SR, Champion HC, Bivalacqua TJ, Hyman AL, Kadowitz PJ. Role of cyclooxygenase-2 in the generation of vasoactive prostanoids in the rat pulmonary and systemic vascular beds. Circulation 2003; 108: 896-901.
28. Baber SR, Hyman AL, Kadowitz PJ. Role of COX-1 and -2 in prostanoid generation and modulation of angiotensin II responses. Am J Physiol Heart Circ Physiol 2003; 285: H2399-410.
29. Qi Z, Cai H, Morrow JD, Breyer MD. Differentiation of cyclooxygenase 1- and 2-derived prostanoids in mouse kidney and aorta. Hypertension 2006; 48: 323-8.
30. Fosslien E. Cardiovascular complications of Non-Steroidal Anti-Inflammatory Drugs. Ann Clin Lab Sci 2005; 35: 347-85.
31. Rubio ME, Baños G, Diaz E, Guarner-Lans V. Effect of age on insulininduced endothelin release and vasoreactivity in hypertriglyceridemic and hypertensive rats. Exp Gerontol 2006; 41: 282-8.
32. Lowry OH, Rosenborough NJ, Farr AL, Randall RJ. Protein measurement with the folin fenol reagent. J Biol Chem 1951; 193: 265-75.
33. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7.
34. Morley JE. The metabolic syndrome and aging. J Gerontol A Biol Sci Med Sci 2004; 59: 139-42.
35. Bauer ME. Stress, glucocorticoids and ageing of the immune system. Stress 2005; 8: 69-83.
36. 2-adrenergic receptor. Diabetes 2012; 61: 692-701.
37. Muzumdar R, Ma X, Atzmon G, Vuguin P, Yang X, Barzilai N. Decrease in glucose-stimulated insulin secretion with aging is independent of insulin action. Diabetes 2004; 53: 441-6.
38. Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endocrinol Metab 2003; 284: E7-12.
39. 2+-dependent mechanism. Diabetes 1995; 44: 1345-8.
40. El Haffidi M, Pérez I, Zamora J, Soto V, Carvajal-Sandoval G, Baños G. Glycine intake decreases plasma free fatty acids, adipose cell size and blood pressure in sucrose-fed rats. Am J Physiol Regul Integr Comp Physiol 2004; 287: R1387-93.
41. Bollheimer LC, Buettner R, Pongratz G, Brunner-Ploss R, Hechtl C, Banas M, et al. Sarcopenia in the aging high-fat fed rat: a pilot study for modeling sarcopenic obesity in rodents. Biogerontology 2012; 13: 609-20.
42. Sakuma K, Yamaguchi A. Sarcopenic obesity and endocrinal adaptation with age. Int J Endocrinol 2013; 2013: 204164.
43. Kobayasi R, Akamine EH, Davel AP. Oxidative stress and inflammatory mediators contribute to endothelial dysfunction in high-fat diet induced obesity in mice. J Hypertens 2010; 28: 2111-9.
44. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875-80.
45. Li JB, Nishida M, Kaimoto K, Asakawa A, Chaolu H, Cheng KC, et al. Effects of aging on the plasma levels of nesfatin-1 and adiponectin. Biomed Rep 2014; 2: 152-6.
46. Song HJ, Oh S, Quan S, Ryu OH, Jeong JY, Hong KS, et al. Gender differences in adiponectin levels and body composition in older adults: Hallym aging study. BMC Geriatrics 2014; 14: 8.
47. Wells JCK. Ethnic variability in adiposity and cardiovascular risk: the variable disease selection hypothesis. Int J Epidemiol 2009; 38: 63-71.
48. Yang R, Barouch LA. Leptin signaling and obesity cardiovascular consequences. Circ Res 2007; 101: 545-59.
49. 2 in rat mesangial cells by a Nonsteroideal Antiinflammatory drug: the role of cyclic AMP. Mol Pharmacol 1998; 53: 385-91.
50. Csiszar A, Wang M, Lakatta E, Ungvari Z. Inflammation and endothelial dysfunction during aging: role of NF-kB. J Appl Physiol 2008; 105: 1333-41.
51. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007; 128: 92-105.
52. Mustafa AK, Gadalla MM, Snyder SH. Signaling by Gasotransmitters. Sci Signal 2009; 2: re2.
53. 2a mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. Circ Res 2009; 104: 228-35.
54. Gomez E, Schwendemann C, Roger S, Simonet S, Paysant J, Courchay C, et al. Aging and prostacyclin responses in aorta and platelets from WKY and SHR rats. Am J Physiol Heart Circ Physiol 2008; 295: H2198-211.
55. Morgan T, Anderson A. The effect of Nonsteroidal Anti-Inflammatory Drugs on blood pressure in patients treated with different antihypertensive drugs. J Clin Hypertens 2003; 5: 53-7.
56. Polonia J. Interaction of antihypertensive drugs with anti-inflammatory drugs. Cardiology 1997; 88: 47-51.
57. Brueggemann LI, Mani BK, Mackie AR, Cribbs LL, Byron KL. Novel actions of nonsteroidal anti-inflammatory drugs on vascular ion channels: accounting for cardiovascular side effects and identifying new therapeutic applications. Mol Cell Pharmacol 2010; 2: 15-9.
58. Taubert D, Berkels R, Grosser N, Schröder H, Gründemann D, Schömig E. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. Br J Pharmacol 2004; 143: 159-65.
59. Wong MSK, Man RYK, Vanhoutte PM. Calcium-independent phospholipase A2 plays a key role in the endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2010; 298: H1260-6.
60. Beasley D. COX-2 and cytosolic PLA2 mediate IL-1b-induced cAMP production in human vascular smooth muscle cells. Am J Physiol 1999; 276: H1369-78.
61. Luo SF, Lin WN, Yang CM, Lee CW, Liao CH, Leu YL, et al. Induction of cytosolic phospholipase A2 by lipopolysaccharide in canine tracheal smooth muscle cells: involvement of MAPKs and NF-kB pathways. Cell Signal 2006; 18: 1201-11.
62. Lin CC, Lin WN, Wang WJ, Sun CC, Tung WH, Wang HH, et al. Functional coupling expression of COX-2 and cPLA2 induced by ATP in rat vascular smooth muscle cells: role of ERK1/2, p38 MAPK, and NFkB. Cardiovasc Res 2009; 82: 522-31.
63. Barton M. Ageing as a determinant of renal and vascular disease: role of endothelial factors. Nephrol Dial Transplant 2005; 20: 485-90.
64. Rubio-Ruiz ME, Díaz-Díaz E, Cárdenas-León M, Argüelles-Medina R, Sánchez-Canales P, Larrea-Gallo F, et al. Glycation does not modify bovine serum albumin (BSA)-induced reduction of rat aortic relaxation: the response to glycated and nonglycated BSA is lost in metabolic syndrome. Glycobiology 2008; 18: 517-25.